

**EFFECTIVE DATE:** 10|01|2015

**POLICY LAST UPDATED:** 07|07|2015

## OVERVIEW

Electromagnetic navigation bronchoscopy (ENB) is intended to enhance standard bronchoscopy by providing a 3-dimensional roadmap of the lungs and real-time information about the position of the steerable probe during bronchoscopy. The purpose of ENB is to allow navigation to distal regions of the lungs, so that suspicious lesions can undergo biopsy and to allow for placement of fiducial markers.

## MEDICAL CRITERIA

Not applicable

## PRIOR AUTHORIZATION

Not applicable

## POLICY STATEMENT

### BlueCHiP for Medicare and Commercial Products

Electromagnetic navigation bronchoscopy is considered not medically necessary for use with flexible bronchoscopy for the diagnosis of pulmonary lesions and mediastinal lymph nodes.

Electromagnetic navigation bronchoscopy is considered not medically necessary for the placement of fiducial markers.

## COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary.

## BACKGROUND

ENB uses computed tomography (CT) scans to improve the ability of standard bronchoscopic procedures to reach lesions in the periphery of the lungs. Overall, data are insufficient to determine the risks and benefits of ENB compared with standard approaches to diagnose peripheral lesions.

Pulmonary nodules are identified on plain chest radiographs or chest CT scans. Although most of these nodules are benign, some are cancerous, and early diagnosis of lung cancer is desirable because of the poor prognosis when it is diagnosed later in the disease course. The method used to diagnose lung cancer depends on a number of factors, including lesion size and location, as well as the clinical history and status of the patient. There is generally greater diagnostic success with centrally located and larger lesions.

Peripheral lung lesions and solitary pulmonary nodules (most often defined as asymptomatic nodules <6 mm) are more difficult to evaluate than larger, centrally located lesions. There are several options for diagnosing them; none of the methods are ideal for safely and accurately diagnosing malignant disease.

Recent advances in technology have led to enhancements that may increase the yield of established diagnostic methods. CT scanning equipment can be used to guide bronchoscopy and bronchoscopic transbronchial needle biopsy but have the disadvantage of exposing the patient and staff to radiation. Endobronchial ultrasound (EBUS) by radial probes, previously used in the perioperative staging of lung cancer, can also be

used to locate and guide sampling of peripheral lesions. EBUS is reported to increase the diagnostic yield of flexible bronchoscopy to at least 82%, regardless of the size and location of the lesion.

Another proposed enhancement to standard bronchoscopy is ENB. This technology uses CT scans to improve the ability of standard bronchoscopic procedures to reach lesions in the periphery of the lungs. The InReach™ system was the first ENB system cleared for marketing by FDA. The 3 phases of the procedure using the InReach system are as follows:

1. **Planning phase:** Proprietary software is used to take previously taken CT scans and construct a 3-dimensional image of the patient's lungs, with anatomical landmarks identified. The file containing this information is transferred to a computer on the InReach computer console for use during the procedure;
2. **Registration phase:** A steerable navigation catheter is placed through the working channel of a standard bronchoscope. The anatomical landmarks identified in the planning phase are viewed on the 3-dimensional image from phase 1, and these virtual images are correlated with the actual image from the video bronchoscope. The steerable navigation catheter is placed at the same site as the virtual markers, and the position of each is marked using a foot pedal;
3. **Navigation phase:** The steerable navigation catheter is moved toward the target, and the real-time location of the catheter's tip is displayed on the CT images. When the navigation catheter reaches the target, it is locked in place and the working guide is retracted.

Once the navigation catheter is in place, any endoscopic tool can be inserted through the channel in the catheter to the target. This includes insertion of transbronchial forceps to biopsy the lesion. In addition, the guide catheter can be used to place fiducial markers. Markers are loaded in the proximal end of the catheter with a guide wire inserted through the catheter.

Electromagnetic navigation bronchoscopy uses computed tomography scans to improve the ability of standard bronchoscopic procedures to reach lesions in the periphery of the lungs. Overall, data are insufficient to determine the risks and benefits of ENB compared with standard approaches to diagnose peripheral lesions. The data are also insufficient to identify which patients might benefit from ENB. Thus, use of this technology is considered not medically necessary.

## **CODING**

### **BlueCHiP for Medicare and Commercial Products**

The following codes are not medically necessary:

31626

31627

## **RELATED POLICIES**

Not applicable

## **PUBLISHED**

Provider Update, August 2015

## **REFERENCES**

1. Rivera MP, Mehta AC, American College of Chest P. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. Sep 2007;132(3 Suppl):131S-148S. PMID 17873165
2. Tape TG. Solitary Pulmonary Nodule. In Black ER et al. eds. *Diagnostic strategies for common medical problems*, 2nd edition. Philadelphia, PA: American College of Physicians; 1999.
3. Gex G, Pralong JA, Combescure C, et al. Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. *Respiration*. 2014;87(2):165-176. PMID 24401166

4. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. *Chest*. Aug 2012;142(2):385-393. PMID 21980059
5. Eberhardt R, Anantham D, Ernst A, et al. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. *Am J Respir Crit Care Med*. Jul 1 2007;176(1):36-41. PMID 17379850
6. Wilson DS, Bartlett BJ. Improved diagnostic yield of bronchoscopy in a community practice: combination of electromagnetic navigation system and rapid on-site evaluation. *J Bronchology Interv Pulmonol*. 2007;14(4):227-232.
7. Eberhardt R, Anantham D, Herth F, et al. Electromagnetic navigation diagnostic bronchoscopy in peripheral lung lesions. *Chest*. Jun 2007;131(6):1800-1805. PMID 17400670
8. Chee A, Stather DR, Maceachern P, et al. Diagnostic utility of peripheral endobronchial ultrasound with electromagnetic navigation bronchoscopy in peripheral lung nodules. *Respirology*. Jul 2013;18(5):784-789. PMID 23521707

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

